Luc Therapeutics

About Luc Therapeutics

Luc Therapeutics is at the forefront of developing innovative treatments for cognitive and movement disorders. The company focuses on creating novel allosteric modulators of ion channels, specifically targeting SK channels and NMDA receptors, which are crucial for neuronal communication. By leveraging extensive industry experience in medicinal chemistry, target selection, drug discovery, and drug optimization, Luc Therapeutics aims to produce drug candidates that offer optimal efficacy with minimal side effects. The company operates in the pharmaceutical industry, serving patients affected by conditions such as essential tremor, schizophrenia, and spinocerebellar ataxia. Luc Therapeutics collaborates with pharmaceutical consortia and instrument companies to validate new diagnostic endpoints, enhancing the accuracy of disease severity measurements beyond traditional observation-based rating scales. The business model revolves around rigorous evaluation and development of drug candidates, with revenue generated through partnerships and potential drug commercialization.